Dr. Layman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Unit 1354
Houston, TX 77030Phone+1 713-745-8401Fax+1 713-794-5039
Summary
- Dr. Rachel Layman, based in Houston, TX, specializes in Oncology with a particular focus on breast cancer and cancer genetics/cancer risk assessment. She completed her fellowship in Hematology and Medical Oncology at the University of Michigan Health System and her residency in Internal Medicine at Case Western Reserve University/University Hospitals Cleveland Medical Center. Dr. Layman's expertise includes medical oncology, breast cancer, familial breast cancer, hormone receptor positive breast cancer, and inflammatory breast cancer. She has contributed extensively to research within her field, authoring numerous publications in leading oncology journals and conducting several clinical trials. Notably, Dr. Layman was recognized with the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR, Epic Systems Corporation in 2012-2013.
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2004 - 2008
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2001 - 2004
Case Western Reserve University School of MedicineClass of 2001
Certifications & Licensure
FL State Medical License 2021 - Present
GA State Medical License 2023 - 2026
TX State Medical License 2016 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
AZ State Medical License 2023 - 2025
LA State Medical License 2023 - 2025- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer Start of enrollment: 2009 Apr 01
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
- Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer Start of enrollment: 2014 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.Vishnu Prasath, Hinda Boutrid, Robert Wesolowski, Mahmoud Abdel-Rasoul, Cynthia Timmers
Breast Cancer Research and Treatment. 2025-02-01 - Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L Graff, Kyong Hwa Park
Journal of Clinical Oncology. 2024-12-18 - Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness.Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen
The Oncologist. 2024-12-06
Press Mentions
HER2 Low and Ultralow Designations Open Door to Expansion of ADCs in Breast CancerDecember 12th, 2024
Pfizer Presents New Evidence of IBRANCE® (Palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019September 24th, 2019- Mom, 30, Details Symptoms of Rare Type of Breast Cancer That Doctors MisdiagnosedOctober 12th, 2023
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
